SentiSense
Ctrl+K
Quick tip: Press
to search stocks
M
MRNA
Moderna Inc.
$52.56
-0.83 (-1.55%)
Summary
Stories
News
Metrics
Fundamentals
Holders
Full institutional holders data is a Pro feature
UpgradeInstitutional Holders
619
tracked filers
Total Institutional Value
$4.1B
619 holders tracked
Report Date
Q4 2025
SEC 13F-HR filing
Notable changes (2)
| Holder | Category | Shares | Value | Weight | Change |
|---|---|---|---|---|---|
VANGUARD GROUP INC | Index Fund | 38.2M | $987.8M | -- | +19116.3% |
STATE STREET CORP | Index Fund | 17.1M | $441.9M | -- | -0.9% |
GEODE CAPITAL MANAGEMENT, LLC | Index Fund | 8.3M | $213.0M | -- | +4.0% |
TWO SIGMA INVESTMENTS, LP | Hedge Fund | 7.5M | $194.5M | -- | +8.2% |
FMR LLC | Other | 7.5M | $193.6M | -- | -39.3% |
Data source: SEC EDGAR 13F-HR filings
Company Profile
Symbol
MRNA
Market Cap
$21.09B
IPO Date
Dec 7, 2018
CEO
Stéphane Bancel
Employees
4,700
Sector
--
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Country
United States
Exchange
--
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Read MoreSimilar Stocks
PFE
Pfizer Inc.
$26.58
-1.04%
NVS
Novartis AG
$153.44
-0.53%